Knight Therapeutics Announces Regulatory Approval of TAVALISSE® in Brazil
· Financial Post
1) ANVISA, Prescribing Information. Approved on May 7, 2026.
2) Tavalisse. Full Prescribing Information. Rigel Pharmaceuticals, 2018, www.tavalisse.com/downloads/pdf/Tavalisse-Full-Prescribing-Information.pdf.
3) National Heart, Lung, and Blood Institute. Immune Thrombocytopenia. U.S. Department of Health and Human Services, https://www.nhlbi.nih.gov/health/immune-thrombocytopenia. Accessed 24 July 2025.
4) Kos, Marek et al. “The Many Faces of Immune Thrombocytopenia: Mechanisms, Therapies, and Clinical Challenges in Oncological Patients.” Journal of clinical medicine vol. 13,22 6738. 8 Nov. 2024, doi:10.3390/jcm13226738
5) Kuter, D. "The treatment of immune thrombocytopenia (ITP) – focus on thrombopoietin receptor agonists" Annals of Blood, vol. 6, 2021. https://aob.amegroups.org/article/view/6335/html. Accessed 24 July 2025.
6) Bussel, James et al. “Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials.” American journal of hematology vol. 93,7 (2018): 921-930. doi:10.1002/ajh.25125 Read More
2) Tavalisse. Full Prescribing Information. Rigel Pharmaceuticals, 2018, www.tavalisse.com/downloads/pdf/Tavalisse-Full-Prescribing-Information.pdf.
3) National Heart, Lung, and Blood Institute. Immune Thrombocytopenia. U.S. Department of Health and Human Services, https://www.nhlbi.nih.gov/health/immune-thrombocytopenia. Accessed 24 July 2025.
4) Kos, Marek et al. “The Many Faces of Immune Thrombocytopenia: Mechanisms, Therapies, and Clinical Challenges in Oncological Patients.” Journal of clinical medicine vol. 13,22 6738. 8 Nov. 2024, doi:10.3390/jcm13226738
5) Kuter, D. "The treatment of immune thrombocytopenia (ITP) – focus on thrombopoietin receptor agonists" Annals of Blood, vol. 6, 2021. https://aob.amegroups.org/article/view/6335/html. Accessed 24 July 2025.
6) Bussel, James et al. “Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials.” American journal of hematology vol. 93,7 (2018): 921-930. doi:10.1002/ajh.25125 Read More
Visit h-doctor.club for more information.